ImmunityBio surges as ANKTIVA revenue jumps 700% in breakthrough 2025
ImmunityBio (NASDAQ:IBRX), the California-based immunotherapy leader, reported explosive 2025 financial results on Monday, signaling its successful transition into a high-growth commercial powerhouse.
The company’s lead asset, ANKTIVA®, generated $113 million in net product revenue for the full year—a staggering 700% increase compared to 2024—driven by rapid adoption in the non-muscle invasive bladder cancer (NMIBC) market.
The commercial momentum was fueled by a 750% surge in unit sales volume, reflecting broad physician uptake and successful integration into oncology treatment pathways.
ImmunityBio maintained a strong growth trajectory through the end of the year, posting a 20% quarter-over-quarter revenue increase in the fourth quarter.
Beyond the balance sheet, 2025 marked a pivotal regulatory expansion for the company.
ImmunityBio now boasts a global footprint spanning 33 countries across four jurisdictions.
Most notably, the company secured its first regulatory approval for ANKTIVA in a new indication: a combination therapy with checkpoint inhibitors for the treatment of lung cancer.
This milestone significantly expands the drug's addressable market beyond urology and into the high-volume thoracic oncology space.
Frequently asked questions
More from United States
Aeries Technology reports $18.1 million Q2 revenue, maintains 2027 outlook
Riskified revenue accelerates 41% to $115.2 million in Q3
Aebi Schmidt cuts 2026 guidance despite Q3 sales growth
Applied Aerospace reports record $182.1 million Q3 revenue
Nayax revenue skyrockets 23% to $128 million as IPS acquisition expands outlook
RUM Group revenue surges 290% to $96.6 million
